Far from it—one of the cafepharma posters who posted on July 23 repeated the canard that NVS/MNTA have 180-day Hatch-Waxman marketing exclusivity for Lovenox.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”